Onset of antidepressant activity: Reexamining the structure of depression and multiple actions of drugs

Depression and Anxiety

Volumn 4, Issue 6, 1996, Pages 257-267

  Katz, Martin M ^a,d   Koslow, Stephen H ^b   Frazer, Alan ^c  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^d NONE   (United States)

Author keywords

atypical antidepressants; effect size measures; lag period; placebo response; selective serotonin reuptake inhibitors; tricyclic antidepressants

Indexed keywords

ANTIDEPRESSANT AGENT; SEROTONIN UPTAKE INHIBITOR;

BEHAVIOR; DEPRESSION; DRUG ACTIVITY; DRUG EFFICACY; DRUG RESPONSE; HUMAN; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

AFFECT; ANTIDEPRESSIVE AGENTS; CLINICAL TRIALS; DEPRESSIVE DISORDER; DRUG MONITORING; HUMANS; PERSONALITY ASSESSMENT; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 0030438778     PISSN: 10914269     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1520-6394(1996)4:6<257::AID-DA1>3.0.CO;2-9     Document Type: Review

References (61)

1. Abraham K (1911) Notes on the psychoanalytical investigation and treatment of manic-depressive insanity and allied conditions. In Jones E (ed). Selected Papers on Psychoanalysis. London: Hogarth Press, pp 137-156.
2. Angst J (1970) Mechanisms of action of imipramine and its therapeutic use. In: Angst J (ed): Tofranil Stampflu and Cie Bern, p 36.
3. Beck AT (1972) Depression: Causes and Treatment. Philadelphia: University of Pennsylvania Press.
4. Blier P, de Montigny C (1994) Current advances and trends in the treatment of depression. Trends Pharmacol Sci 15:220-226.
5. Boyer CL, Feighner JP (1994) Clinical significance of early non-response in depressed patients. Depression 2:32-35.
6. Braithwaite R, Goulding R, Theano G, Bailey J, Coppen A (1972) Plasma concentration of amitriptyline and clinical response. Lancet 1:1297-1300.
7. Carlsson A, Corrodi H, Fuxe K, Hokfelt T (1969) Effect of antidepressant drugs on the depletion of intraneuronal brain 5-hydroxytryptamine stores caused by 4-methyl-α-ethyl-meta-tyramine. Eur J Pharmacol 5:357-366.
8. Casper RC, Katz MM, Bowden CL, Davis JM, Koslow SH, Hanin I (1994) The pattern of physical symptom changes in major depressive disorder following treatment with amitriptyline or imipramine. J Affect Disord 31:151-164.
9. Cohen J (1969) Statistical Power Analysis for the Behavioral Sciences. New York, NY: Academic Press.
10. Coryell W, Coppen A, Zeigler VE, Biggs JT (1982) Early improvement as a predictor of response to amitriptyline and nortriptyline: A comparison of two patient samples. Psychol Med 12:135-139.
11. Derivan A, Entsuah AR, Kikta D (1995) Venlafazine: Measuring the onset of antidepressant action. Psychopharmacol Bull 34:437-445.
12. Derogatis LR, Lipman RS, Rickels K, Uhlenhuth EH, Covi L (1974) The Hopkins Symptom Checklist (HSCL): A measure of primary symptom dimensions. In Pichot P(ed): Psychological Measurements in Psychopharmacology: Modern problems in Pharmacopsychiatry Vol 7. Basel: Karger, pp 79-110.
13. DiMasao A, Weissman, MM, Prusoff BA, Neu C, Zwilling M, Klerman GL (1979) Differential symptom reduction by drugs and psychotherapy in acute depression. Arch Gen Psychiatry 36:1450-1456.
14. Dunbar GC, Cohn JB, Fahre LF, Feighner JP, Fievre RR, Mendels J, Shrivastava RK (1991) A comparison of paroxetine, imipramine and placebo in depressed outpatients. Br J Psychiatry 159:394-398.
15. Endicott J, Spitzer R (1978) A diagnostic interview: the Schedule of Affective Disorders and Schizophrenia. Arch Gen Psychiatry 35:837-844.
16. Frazer A (1994) Antidepressant drugs. Depression 2:1-19.
17. Frazer A, Conway P (1984) Pharmacologic mechanisms of action of antidepressants. Psychiat. Chn North Am 7:575-586.
18. Freud S (1934) Mourning and melancholia. In: Collected Papers, Vol. 4 London. Hogarth Press, pp 153-170.
19. Gachoud JP, Mikkelsen H, Ammar S, Widlocher D, Jouvent R (1992) Theoretical considerations and perspectives on the onset of action of moclobemide. Psychopharmacology 106:S96-S97.
20. Grinker RR Sr, Miller J, Sabshin M, Nunn R, Nnnnally JC (1961) The Phenomena of Depressions. New York: Hoeber.
21. Hamilton M (1960) A rating scale for depression. J Ncurol, Neurocurgery, and Psychiatry 23:56-62.
22. Haskell DS, DiMascio A, Prusoff B (1975) Rapidity of symptom reduction in depressions treated with amitriptyline. J Nerv Ment Dis 160:24-33.
23. Hordern A, Holt NF, Burt CG, Gordon WF (1963) Amitriptyline in depressive states. Brit J Psychiatry 109:815-825.
24. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481.
25. Katz MM, Koslow SH, Berman N, Secunda S, Maas JW, Casper R, Kocsis J, Stokes P (1984) Multivantaged approach to the measurement of behavioral and affect states for clinical and psychobiological research. Psychol Rep. 55:619-791.
26. Katz MM, Koslow SH, Maas JW, Frazer A, Bowden CL, Casper R, Croughan J, Kocsis J, Redmond E (1987) The timing, specificity, and clinical prediction of tricyclic drug effects in depression. Psychol Med 17:297-309.
27. Katz MM, Koslow SH, Maas JW, Frazer A, Kocsis J, Secunda S, Bowden CL, Casper RC (1991) Identifying the specific clinical actions of amitriptyline: Interrelationships of behavior, affect and plasma levels in depression. Psychol Med 21:599-611.
28. Katz MM, Maas JW (1994) Psychopharmacology and the etiology of psychopathological states; Are we looking in the right way? Neuropsychopharmacology 10:139-144.
29. Katz MM, Robins E, Croughan J, Secunda S, Swann A (1982) Behavioral measurement and drug response characteristics of unipolar and bipolar depression. Psychol Med 12:25-36.
30. Katz MM, Secunda S, Hirschfeld RM, Koslow SH (1979) NIMH Clinical Research Branch Collaborative Program on the Psychobiology of Depression. Arch Gen Psychiatry 43-765-771.
31. Kielholz P, Poldinger W (1968) Die behandlung endogener depressionen mit psychopharmaka. Dt med Wschr 93:701-704.
32. Klerman GL (1972) Clinical phenomenology of depression: Implications for research strategy in the psychobiology of the affective disorders. In: Williams TA, Katz MM, Shield JA (eds): Recent Advances in the Psychobiology of the Depressive Illnesses. Washington DC:US Govt. Printing Office, pp 331-339.
33. Kuhn R (1958) The treatment of depressive states with G 22355 (imipramine hydrochloride). Am J Psychiatry 115:459-464.
34. Lader M, Lang RA, Wilson GD (1987) Patterns of improvement of depressed inpatients. Maudsley Monograph No. 30; Oxford University Press.
35. Laska EM, Siegel C (1995) Characterizing onset in psychopharmacological clinical trials. Psychopharmacol Bull 31:29-35.
36. Leber P (1995) Speed of onset. Psychopharmacol Bull 31:37
37. Maas JW, Koslow SH, Davis J, Katz MM, Mendels J, Robins E. Stokes P, Bowden CL (1980) Biological component of the NIMH Clinical Research Branch Collaborative Program on the Psychobiology of Depression I; Background and theoretical considerations. Psychol Med 10:759-776.
38. Montgomery SA (1995a) Are 2-week trials sufficient to indicate efficacy? Psychopharmacol Bull 31:41-44.
39. Montgomery SA (1995b) Rapid onset of action of venlafaxine. Int Clin Psychopharmacol 10: Suppl 2:21-27.
40. Nagayama H, Nagano H, Ikezaki A, Tashiro T (1991) Prediction of efficacy by 1-week test therapy m depression. J Affect Disord 23:213-216.
41. Overall JE (1962) Dimensions of manifest depression. Psychiatric Res 1:239-245.
42. Overall JE (1995) Justifying a "fast acting" claim for antidepressant drugs. Psychopharmacol Bull 31:45-55.
43. Parker G, Hadzi-Pavlovic D, Boyce P, Wilhelm K, Brodzky H, Mitchell P, Hickie I, Eyers K (1990) Classifying depression by mental state signs. Brit J Psychiatry 157:55-65.
44. Paykel ES (1971) Classification of depressed patients: A cluster analysis derived grouping. BrJ Psychiatry 118:275-288.
45. Preskorn SH (1994) Antidepressant drug selection: Criteria and options. J Clin Psychiatry 55:6-22.
46. Prien RF, Blaine JD, Levin J, (1985) Antidepressant drug therapy. The role of the new antidepressants. Hosp Community Psychiatry 36:513-516.
47. Quitkin FM, McGrath PJ, Rabkin JG, Stewart JW, Harrison W, Ross DC, Tricamo E, Fleiss J, Markowitz J, Klein DF (1991b) Different types of placebo response in patients receiving antidepressants. Am J Psychiatry 148:197-204.
48. Quitkin FM, McGrath PJ, Stewart JW, Ocepek-Welikson K, Taylor BP, Nunes E, Deliyanmdes D, Agosti V, Donovan SJ, Petkova E, Klein DF (1996a) Chronological milestones to guide drug change. Arch Gen Psychiatry 53-785-792.
49. Quitkin FM, McGrath PJ, Stewart JW, Taylor BP, Klein DF, (1996b) Can the effects of antidepressants be observed in the first two weeks? Neuropsychopharmacology 15.390-394.
50. Quitkin FM, Rabkin JG, Markowitz JM, Stewart JW, McGrath PJ, Harrison W (1987) Use of pattern analysis to identify true drug response; A replication. Arch Gen Psychiatry 44: 259-264.
51. Quitkin FM, Rabkin JG, Ross D, Stewart JW (1984) Identification of true drug response to antidepressants. Arch Gen Psychiatry 41:782-786.
52. Quitkin FM, Rabkin JG, Stewart JW, McGrath PJ, Harrison W, Roes D, Tricamo E, Fleiss J, Markowitz J, Klein DF (1991a) Heterogeneity of clinical response during placebo treatment. Am J Psychiatry 148:193-196.
53. Quitkin FM, Stewart JW, McGrath PJ, Nunes E, Ocepek-Welikson K, Tricamo E, Rabkin JG, Kein DF (1993) Further evidence that a placebo response to antidepressants can be identified. Am J Psychiatry 150:566-570.
54. Rickels J, Derivan A, Entsuah R, Miska S, Rudolph R (1995) Rapid onset of antidepressant activity with venlafaxine treatment. Depression 3:146-153.
55. Rothchild R, Quitkin FM (1992) Review of the use of pattern analysis to differentiate true drug and placebo responses. Psychother Psychosom 58:170-177.
56. Small JG, Milstein V, Kellams JJ, Small IF (1981) Comparative onset of improvement in depressive symptomatology with drug treatment electroconvulsive therapy, and placebo. J Clin Psychopharmacol 1(Suppl. 6):62-69S.
57. Smith WT, Glaudin V, Panagides J, Gilvary E (1990) Mirtazapine vs amitriptyline vs placebo in the treatment of major depressive disorder. Psychopharmacol Bull 26:191-196.
58. Stassen HH, Delini-Stula A, Angst J (1993) Time course of improvement under antidepressant treatment: A survival-analytical approach. Eur Neuropsychopharmacol 3:127-135.
59. Stokes PE. Stoll PM, Kosbw SH, Maas, JW, Davis JM, Swann AC, Robins E (1984) Pretreatment DST and hypothalamic-pituitaryadrenocortical function in depressed patients and comparison groups. Arch Gen Psychiatry 41:257-267.
60. Tollefson TG, Holman SL (1994) How long to onset of antide-pressant action: A meta-analysis of patients treated with fluoxetine or placebo. Int Clin Psychopharmacul 9:245-250.
61. Ziegler V, Clayton P, Biggs J (1977) A comparison study of amitriptyline and nortrvptiline with plasma levels. Arch Gen Psychiatry 34:607-612.